FINWIRES · TerminalLIVE
FINWIRES

Raymond James Upgrades Tvardi Therapeutics to Outperform From Market Perform

By

Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

BofA Securities Initiates Coverage on SPX Technologies With Buy Rating, $235 Price Target

SpaceX (SPCX) has an average rating of overweight and mean price target of $220.81, according to analysts polled by FactSet.Price: $219.24, Change: $-12.95, Percent Change: -5.58%

$SPXC
Research

Wells Fargo Upgrades MGM Resorts International to Equalweight From Underweight, Price Target is $48.30

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $48.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $46.81, Change: $-0.07, Percent Change: -0.15%

$MGM
Research

LifeSci Capital Downgrades Crinetics Pharmaceuticals to Market Perform From Outperform, Price Target is $85

Crinetics Pharmaceuticals Inc (CRNX) has an average rating of overweight and mean price target of $83.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CRNX